// App-Quantinova.ai

: Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Achievement of Absolute PASI Thresholds in the Phase 3 POETYK PSO-1 and PSO-2 Trials

Researchers

Presenter

  • Mark Lebwohl

Principal Investigators

  • Melinda Gooderham

  • Richard B Warren

  • Diamant Thaçi

  • Peter Foley

  • Alice B Gottlieb

  • Subhashis Banerjee

  • Lauren Hippeli

  • Renata M Kisa

  • Christopher E M Griffiths

Medical Centers

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • SKiN Centre for Dermatology and Probity Medical Research, Peterborough, ON, Canada

  • The Dermatology Centre, Salford Royal NHS Foundations Trust, Manchester NIHR Biomedical Research Centre, The University of Manchester, University of Manchester, Manchester, UK

  • University of Lubeck, Lubeck, Germany

  • Skin Health Institute, Carlton, VIC, Australia

  • Bristol-Myers Sqiubb, Princeton, NJ

Locations

  • Australia

  • United Kingdom

  • Canada

  • United States

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriasis

Biomarkers

  • N/A

Drug/Treatment

  • Apremilast

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • NCT03624127

  • NCT03611751

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved